Protective effect of melatonin versus montelukast in cisplatin‐induced seminiferous tubule damage in rats
We compared the protective effects of melatonin and montelukast against cisplatin‐induced testicular damage. Adult male rats were assigned to one of four groups: a control group, a cisplatin (Cis) group treated with a single intraperitoneal injection of 7 mg/kg cisplatin, a cisplatin + melatonin gro...
Gespeichert in:
| Veröffentlicht in: | Andrologia 2018-11, Vol.50 (9), p.e13077-n/a |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 9 |
| container_start_page | e13077 |
| container_title | Andrologia |
| container_volume | 50 |
| creator | El‐shafaei, Adel Abdelmaksoud, Rania Elshorbagy, Amany Zahran, Noha Elabd, Rana |
| description | We compared the protective effects of melatonin and montelukast against cisplatin‐induced testicular damage. Adult male rats were assigned to one of four groups: a control group, a cisplatin (Cis) group treated with a single intraperitoneal injection of 7 mg/kg cisplatin, a cisplatin + melatonin group (Cis‐Mel) and a cisplatin + montelukast group (Cis‐Mon) each treated with the same dose of cisplatin together with either oral melatonin (20 mg/kg) or oral montelukast (10 mg/kg) in 2 ml water from day 1 to day 10 starting on the day of the cisplatin injection. Cisplatin‐induced oxidative stress, with a significant increase in testicular malonedialdehyde (MDA), decreased testicular glutathione (GSH), histological testicular damage and body weight loss. Additionally, increased abnormal sperm forms and decreased count and motility were noted. Melatonin and montelukast both rescued GSH concentrations, increased sperm count and motility and decreased abnormal forms. Montelukast resulted in better rescue of weight loss, while greater improvement in sperm count and testicular pathology, and a trend for decreased MDA were noted with melatonin. These findings suggest that melatonin and montelukast protect against different aspects of cisplatin‐induced toxicity. Future studies should assess whether both drugs may have additive benefit when used in combination. |
| doi_str_mv | 10.1111/and.13077 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2117754108</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2117754108</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4547-42c96576e042b5888da22567290e2d1359d1598b6da28959d8421be3ad668f343</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EolXpgh9AkVixSOtn7Cwr3lIFLGAdOfEEuc2j2ElRd3wC38iX4NLCjtnMzNWZO9JF6JTgCQk11Y2ZEIalPEBDwlkaYyrpIRpihlnMRZIO0Nj7BQ7FhZScH6MBw5ikTCVDtHxybQdFZ9cQQVmGKWrLqIZKd21jm2gNzvc-qtumg6pfat9FQS2sXwXCNl8fn7YxfQEm8lDbxpbg2sB3fd5XEBld61fYXjjd-RN0VOrKw3jfR-jl5vr58i6eP97eX87mccEFlzGnRZoImQDmNBdKKaMpFYmkKQZqCBOpISJVeRJ0lYZNcUpyYNokiSoZZyN0vvNdufatB99li7Z3TXiZUUKkFJxgFaiLHVW41nsHZbZyttZukxGcbZPNQrLZT7KBPds79nkN5o_8zTEA0x3wbivY_O-UzR6udpbf8ruDMQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2117754108</pqid></control><display><type>article</type><title>Protective effect of melatonin versus montelukast in cisplatin‐induced seminiferous tubule damage in rats</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>El‐shafaei, Adel ; Abdelmaksoud, Rania ; Elshorbagy, Amany ; Zahran, Noha ; Elabd, Rana</creator><creatorcontrib>El‐shafaei, Adel ; Abdelmaksoud, Rania ; Elshorbagy, Amany ; Zahran, Noha ; Elabd, Rana</creatorcontrib><description>We compared the protective effects of melatonin and montelukast against cisplatin‐induced testicular damage. Adult male rats were assigned to one of four groups: a control group, a cisplatin (Cis) group treated with a single intraperitoneal injection of 7 mg/kg cisplatin, a cisplatin + melatonin group (Cis‐Mel) and a cisplatin + montelukast group (Cis‐Mon) each treated with the same dose of cisplatin together with either oral melatonin (20 mg/kg) or oral montelukast (10 mg/kg) in 2 ml water from day 1 to day 10 starting on the day of the cisplatin injection. Cisplatin‐induced oxidative stress, with a significant increase in testicular malonedialdehyde (MDA), decreased testicular glutathione (GSH), histological testicular damage and body weight loss. Additionally, increased abnormal sperm forms and decreased count and motility were noted. Melatonin and montelukast both rescued GSH concentrations, increased sperm count and motility and decreased abnormal forms. Montelukast resulted in better rescue of weight loss, while greater improvement in sperm count and testicular pathology, and a trend for decreased MDA were noted with melatonin. These findings suggest that melatonin and montelukast protect against different aspects of cisplatin‐induced toxicity. Future studies should assess whether both drugs may have additive benefit when used in combination.</description><identifier>ISSN: 0303-4569</identifier><identifier>EISSN: 1439-0272</identifier><identifier>DOI: 10.1111/and.13077</identifier><identifier>PMID: 30019386</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Acetates - pharmacology ; Acetates - therapeutic use ; Animals ; Antineoplastic Agents - adverse effects ; Antioxidants - pharmacology ; Antioxidants - therapeutic use ; Body weight ; Body Weight - drug effects ; Body weight loss ; Chemotherapy ; Cisplatin ; Cisplatin - adverse effects ; Drug Evaluation, Preclinical ; Drug screening ; Glutathione ; Injection ; Leukotriene Antagonists - pharmacology ; Leukotriene Antagonists - therapeutic use ; Male ; Melatonin ; Melatonin - pharmacology ; Melatonin - therapeutic use ; Montelukast ; Motility ; Organ Size - drug effects ; Oxidative stress ; Oxidative Stress - drug effects ; Quinolines - pharmacology ; Quinolines - therapeutic use ; Rats, Wistar ; Rodents ; Semen Analysis ; Seminiferous tubule ; Seminiferous Tubules - drug effects ; Seminiferous Tubules - pathology ; Sperm ; Testes ; Testicular Diseases - chemically induced ; Testicular Diseases - prevention & control ; Toxicity</subject><ispartof>Andrologia, 2018-11, Vol.50 (9), p.e13077-n/a</ispartof><rights>2018 Blackwell Verlag GmbH</rights><rights>2018 Blackwell Verlag GmbH.</rights><rights>Copyright © 2018 Blackwell Verlag GmbH</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4547-42c96576e042b5888da22567290e2d1359d1598b6da28959d8421be3ad668f343</citedby><cites>FETCH-LOGICAL-c4547-42c96576e042b5888da22567290e2d1359d1598b6da28959d8421be3ad668f343</cites><orcidid>0000-0002-8624-860X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fand.13077$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fand.13077$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27911,27912,45561,45562</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30019386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>El‐shafaei, Adel</creatorcontrib><creatorcontrib>Abdelmaksoud, Rania</creatorcontrib><creatorcontrib>Elshorbagy, Amany</creatorcontrib><creatorcontrib>Zahran, Noha</creatorcontrib><creatorcontrib>Elabd, Rana</creatorcontrib><title>Protective effect of melatonin versus montelukast in cisplatin‐induced seminiferous tubule damage in rats</title><title>Andrologia</title><addtitle>Andrologia</addtitle><description>We compared the protective effects of melatonin and montelukast against cisplatin‐induced testicular damage. Adult male rats were assigned to one of four groups: a control group, a cisplatin (Cis) group treated with a single intraperitoneal injection of 7 mg/kg cisplatin, a cisplatin + melatonin group (Cis‐Mel) and a cisplatin + montelukast group (Cis‐Mon) each treated with the same dose of cisplatin together with either oral melatonin (20 mg/kg) or oral montelukast (10 mg/kg) in 2 ml water from day 1 to day 10 starting on the day of the cisplatin injection. Cisplatin‐induced oxidative stress, with a significant increase in testicular malonedialdehyde (MDA), decreased testicular glutathione (GSH), histological testicular damage and body weight loss. Additionally, increased abnormal sperm forms and decreased count and motility were noted. Melatonin and montelukast both rescued GSH concentrations, increased sperm count and motility and decreased abnormal forms. Montelukast resulted in better rescue of weight loss, while greater improvement in sperm count and testicular pathology, and a trend for decreased MDA were noted with melatonin. These findings suggest that melatonin and montelukast protect against different aspects of cisplatin‐induced toxicity. Future studies should assess whether both drugs may have additive benefit when used in combination.</description><subject>Acetates - pharmacology</subject><subject>Acetates - therapeutic use</subject><subject>Animals</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antioxidants - pharmacology</subject><subject>Antioxidants - therapeutic use</subject><subject>Body weight</subject><subject>Body Weight - drug effects</subject><subject>Body weight loss</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Cisplatin - adverse effects</subject><subject>Drug Evaluation, Preclinical</subject><subject>Drug screening</subject><subject>Glutathione</subject><subject>Injection</subject><subject>Leukotriene Antagonists - pharmacology</subject><subject>Leukotriene Antagonists - therapeutic use</subject><subject>Male</subject><subject>Melatonin</subject><subject>Melatonin - pharmacology</subject><subject>Melatonin - therapeutic use</subject><subject>Montelukast</subject><subject>Motility</subject><subject>Organ Size - drug effects</subject><subject>Oxidative stress</subject><subject>Oxidative Stress - drug effects</subject><subject>Quinolines - pharmacology</subject><subject>Quinolines - therapeutic use</subject><subject>Rats, Wistar</subject><subject>Rodents</subject><subject>Semen Analysis</subject><subject>Seminiferous tubule</subject><subject>Seminiferous Tubules - drug effects</subject><subject>Seminiferous Tubules - pathology</subject><subject>Sperm</subject><subject>Testes</subject><subject>Testicular Diseases - chemically induced</subject><subject>Testicular Diseases - prevention & control</subject><subject>Toxicity</subject><issn>0303-4569</issn><issn>1439-0272</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EolXpgh9AkVixSOtn7Cwr3lIFLGAdOfEEuc2j2ElRd3wC38iX4NLCjtnMzNWZO9JF6JTgCQk11Y2ZEIalPEBDwlkaYyrpIRpihlnMRZIO0Nj7BQ7FhZScH6MBw5ikTCVDtHxybQdFZ9cQQVmGKWrLqIZKd21jm2gNzvc-qtumg6pfat9FQS2sXwXCNl8fn7YxfQEm8lDbxpbg2sB3fd5XEBld61fYXjjd-RN0VOrKw3jfR-jl5vr58i6eP97eX87mccEFlzGnRZoImQDmNBdKKaMpFYmkKQZqCBOpISJVeRJ0lYZNcUpyYNokiSoZZyN0vvNdufatB99li7Z3TXiZUUKkFJxgFaiLHVW41nsHZbZyttZukxGcbZPNQrLZT7KBPds79nkN5o_8zTEA0x3wbivY_O-UzR6udpbf8ruDMQ</recordid><startdate>201811</startdate><enddate>201811</enddate><creator>El‐shafaei, Adel</creator><creator>Abdelmaksoud, Rania</creator><creator>Elshorbagy, Amany</creator><creator>Zahran, Noha</creator><creator>Elabd, Rana</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0002-8624-860X</orcidid></search><sort><creationdate>201811</creationdate><title>Protective effect of melatonin versus montelukast in cisplatin‐induced seminiferous tubule damage in rats</title><author>El‐shafaei, Adel ; Abdelmaksoud, Rania ; Elshorbagy, Amany ; Zahran, Noha ; Elabd, Rana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4547-42c96576e042b5888da22567290e2d1359d1598b6da28959d8421be3ad668f343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acetates - pharmacology</topic><topic>Acetates - therapeutic use</topic><topic>Animals</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antioxidants - pharmacology</topic><topic>Antioxidants - therapeutic use</topic><topic>Body weight</topic><topic>Body Weight - drug effects</topic><topic>Body weight loss</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Cisplatin - adverse effects</topic><topic>Drug Evaluation, Preclinical</topic><topic>Drug screening</topic><topic>Glutathione</topic><topic>Injection</topic><topic>Leukotriene Antagonists - pharmacology</topic><topic>Leukotriene Antagonists - therapeutic use</topic><topic>Male</topic><topic>Melatonin</topic><topic>Melatonin - pharmacology</topic><topic>Melatonin - therapeutic use</topic><topic>Montelukast</topic><topic>Motility</topic><topic>Organ Size - drug effects</topic><topic>Oxidative stress</topic><topic>Oxidative Stress - drug effects</topic><topic>Quinolines - pharmacology</topic><topic>Quinolines - therapeutic use</topic><topic>Rats, Wistar</topic><topic>Rodents</topic><topic>Semen Analysis</topic><topic>Seminiferous tubule</topic><topic>Seminiferous Tubules - drug effects</topic><topic>Seminiferous Tubules - pathology</topic><topic>Sperm</topic><topic>Testes</topic><topic>Testicular Diseases - chemically induced</topic><topic>Testicular Diseases - prevention & control</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>El‐shafaei, Adel</creatorcontrib><creatorcontrib>Abdelmaksoud, Rania</creatorcontrib><creatorcontrib>Elshorbagy, Amany</creatorcontrib><creatorcontrib>Zahran, Noha</creatorcontrib><creatorcontrib>Elabd, Rana</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Andrologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El‐shafaei, Adel</au><au>Abdelmaksoud, Rania</au><au>Elshorbagy, Amany</au><au>Zahran, Noha</au><au>Elabd, Rana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protective effect of melatonin versus montelukast in cisplatin‐induced seminiferous tubule damage in rats</atitle><jtitle>Andrologia</jtitle><addtitle>Andrologia</addtitle><date>2018-11</date><risdate>2018</risdate><volume>50</volume><issue>9</issue><spage>e13077</spage><epage>n/a</epage><pages>e13077-n/a</pages><issn>0303-4569</issn><eissn>1439-0272</eissn><abstract>We compared the protective effects of melatonin and montelukast against cisplatin‐induced testicular damage. Adult male rats were assigned to one of four groups: a control group, a cisplatin (Cis) group treated with a single intraperitoneal injection of 7 mg/kg cisplatin, a cisplatin + melatonin group (Cis‐Mel) and a cisplatin + montelukast group (Cis‐Mon) each treated with the same dose of cisplatin together with either oral melatonin (20 mg/kg) or oral montelukast (10 mg/kg) in 2 ml water from day 1 to day 10 starting on the day of the cisplatin injection. Cisplatin‐induced oxidative stress, with a significant increase in testicular malonedialdehyde (MDA), decreased testicular glutathione (GSH), histological testicular damage and body weight loss. Additionally, increased abnormal sperm forms and decreased count and motility were noted. Melatonin and montelukast both rescued GSH concentrations, increased sperm count and motility and decreased abnormal forms. Montelukast resulted in better rescue of weight loss, while greater improvement in sperm count and testicular pathology, and a trend for decreased MDA were noted with melatonin. These findings suggest that melatonin and montelukast protect against different aspects of cisplatin‐induced toxicity. Future studies should assess whether both drugs may have additive benefit when used in combination.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30019386</pmid><doi>10.1111/and.13077</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8624-860X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0303-4569 |
| ispartof | Andrologia, 2018-11, Vol.50 (9), p.e13077-n/a |
| issn | 0303-4569 1439-0272 |
| language | eng |
| recordid | cdi_proquest_journals_2117754108 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Acetates - pharmacology Acetates - therapeutic use Animals Antineoplastic Agents - adverse effects Antioxidants - pharmacology Antioxidants - therapeutic use Body weight Body Weight - drug effects Body weight loss Chemotherapy Cisplatin Cisplatin - adverse effects Drug Evaluation, Preclinical Drug screening Glutathione Injection Leukotriene Antagonists - pharmacology Leukotriene Antagonists - therapeutic use Male Melatonin Melatonin - pharmacology Melatonin - therapeutic use Montelukast Motility Organ Size - drug effects Oxidative stress Oxidative Stress - drug effects Quinolines - pharmacology Quinolines - therapeutic use Rats, Wistar Rodents Semen Analysis Seminiferous tubule Seminiferous Tubules - drug effects Seminiferous Tubules - pathology Sperm Testes Testicular Diseases - chemically induced Testicular Diseases - prevention & control Toxicity |
| title | Protective effect of melatonin versus montelukast in cisplatin‐induced seminiferous tubule damage in rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T22%3A30%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protective%20effect%20of%20melatonin%20versus%20montelukast%20in%20cisplatin%E2%80%90induced%20seminiferous%20tubule%20damage%20in%20rats&rft.jtitle=Andrologia&rft.au=El%E2%80%90shafaei,%20Adel&rft.date=2018-11&rft.volume=50&rft.issue=9&rft.spage=e13077&rft.epage=n/a&rft.pages=e13077-n/a&rft.issn=0303-4569&rft.eissn=1439-0272&rft_id=info:doi/10.1111/and.13077&rft_dat=%3Cproquest_cross%3E2117754108%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2117754108&rft_id=info:pmid/30019386&rfr_iscdi=true |